Last reviewed · How we verify
Prilocaine 0.66%
Prilocaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.
Prilocaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Local anesthesia for infiltration, nerve blocks, and topical application.
At a glance
| Generic name | Prilocaine 0.66% |
|---|---|
| Also known as | Citanest |
| Sponsor | Bozyaka Training and Research Hospital |
| Drug class | Local anesthetic (amide class) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Prilocaine works by reversibly inhibiting sodium influx through voltage-gated sodium channels in nerve fibers, which stabilizes the neuronal membrane and prevents depolarization. This action blocks the conduction of nerve impulses in sensory, motor, and autonomic nerves, resulting in local anesthesia. The drug is metabolized hepatically and has a relatively rapid onset and intermediate duration of action.
Approved indications
- Local anesthesia for infiltration, nerve blocks, and topical application
Common side effects
- Methemoglobinemia
- Allergic reactions
- Systemic toxicity (CNS and cardiovascular effects at high doses)
- Local tissue irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prilocaine 0.66% CI brief — competitive landscape report
- Prilocaine 0.66% updates RSS · CI watch RSS
- Bozyaka Training and Research Hospital portfolio CI